Change in testing for blood glucose during the COVID-19 pandemic, United States 2019–2021
Authors' conclusion
Testing for blood glucose decreased in the US during the COVID-19 pandemic. This may have delayed diagnosis and treatment of prediabetes and diabetes, underscoring the importance of continued access to diabetes screening during pandemics.
Study context
- Population
- United States (US) adults aged ≥18 years without reported diagnosed diabetes; mean age between 46.4 and 46.8 years
- Participants
- 82,594 adults
- Exposure
- Blood glucose testing in 2021 vs 2019
- Outcome
- Prevalence of testing for blood glucose within 12 months
Methodological detailsNational Health Interview Survey 2019–2021
- National Health Interview Survey 2019–2021
Main finding
As reported in the abstract
Blood glucose testing within 12 months, overall
Observational data: associations, not effects.
Further findings
Prevalence of blood glucose testing within 12 months among adults meeting the USPSTF 2015 screening recommendation
- Prevalence decreased from 73.4 % (95 % CI 72.2 %, 74.6 %) to 69.5 % (95 % CI 68.3 %, 70.6 %)
Testing by subgroup
- Decreases in testing observed in most groups; extent of decline differed by subgroups
Original publication
Change in testing for blood glucose during the COVID-19 pandemic, United States 2019–2021. Diabetes Res Clin Pract. Published 29 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →